Mental Health 2022: Ketamine Could be a Game-Changer in the Treatment of Anxiety

Psychedelics could be a game-changer in the treatment of mental health. So far, studies show how useful they can be in treating mental health issues, such as obsessive compulsive disorder, PTSD, opioid addiction, alcoholism, depression, and anxiety to name a few. Ketamine could help treat mood and anxiety, for example. In fact, according to The New Yorker, “Researchers began studying it as a treatment for depression, and, in 2006, the National Institute of Mental Health concluded that a single intravenous dose of ketamine had rapid antidepressant effects. Around three hundred clinical trials have since been held; the broad consensus is that ketamine relieves symptoms of depression for a period that can last days or weeks, during which time talk therapy often proves more effective than normal.” That’s could all be big news for companies such as NeonMind Biosciences (CSE:NEON) (OTC:NMDBF), atai Life Sciences (NASDAQ:ATAI), Seelos Therapeutics (NASDAQ:SEEL), Field Trip Health Ltd. (NASDAQ:FTRP)(TSX:FTRPF), and Numinus Wellness Inc. (TSX:NUMI)(OTC:NUMIF).

Look at NeonMind Biosciences (CSE:NEON)(OTC:NMDBF)

NeonMind Biosciences, an integrated drug development and wellness company, announced today the appointment of Dr. Daniel Bainbridge, MD, FRCPC, past President of the Canadian Anesthesiologists Society, Professor from the Department of Anesthesia and Perioperative Medicine at the University of Western Ontario, and Anesthesia Consultant at London Health Sciences Centre, to its Specialty Clinics Advisory Board.

NeonMind’s medical services division is establishing specialty clinics to enhance access to interventional psychiatry treatments including intravenous ketamine treatment which has shown promise as a rapid treatment for mood and anxiety disorders and has been included as a recommended treatment into Canadian guidelines by the Canadian Network for Mood and Anxiety Treatments1. Dr. Bainbridge will utilize his substantial experience to ensure NeonMind’s protocols, procedures, training, and practices of administering intravenous ketamine are best-in-class and practical from a safety perspective. With over 20 years as a practicing anesthesiologist and his leadership role with the Canadian Anesthesiologists Society, Dr. Bainbridge has vast experience with ketamine and a large network of contacts for NeonMind to train and employ to assure patient safety.

“We are excited to welcome the Canadian leader in anesthesiology, Dr. Bainbridge, to our Specialty Clinics Advisory Board. At NeonMind, we are focused on enhancing access to interventional psychiatry to help address the mental health crisis, including IV-ketamine for mood and anxiety disorders. Safety is of utmost importance for NeonMind’s specialty clinics and, with Dr. Bainbridge’s involvement in building our programs, we can assure patients and healthcare providers they are receiving best-in-class care for their IV-ketamine administration. He will prove invaluable to enhancing access and wider adoption of NeonMind’s IV-ketamine treatment programs,” said Robert Tessarolo, President & CEO of NeonMind.

Dr. Bainbridge commented, “The evidence supports that IV-ketamine is safe and well tolerated at the therapeutic doses used to treat patients suffering from mood and anxiety disorders. The ketamine doses used are magnitudes lower than for procedural sedation, let alone general anesthesia. Ketamine administration requires specific procedures and expertise and can be safely provided in specialty clinics with the appropriately trained health care provider. My colleagues at NeonMind understand this with the aim of enhancing access to this transformational treatment for mood and anxiety disorders utilizing safe and effective care programs. I am excited to work with NeonMind in developing IV-ketamine administration practices and establishing a clinic network to enhance access to these treatment programs for patients in need.”

Other related developments from around the markets include:

atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the U.S. Food and Drug Administration (FDA) has given Investigational New Drug (IND) clearance to conduct a clinical DDI study of PCN-101 (R-ketamine). atai plans to initiate the study early this year through its platform company Perception Neuroscience. The unique properties of PCN-101 could offer a differentiated profile to currently available antidepressants and address key patient needs, including the potential of rapid action and anti-suicidal effect. Rapid onset of action is particularly important in this patient population, but frontline selective serotonin reuptake inhibitors (SSRIs) can take up to 12 weeks before providing maximal benefit, while suicidality affects as much as 30% of treatment-resistant depression (TRD) patients at least once during their lifetime.

iX Biopharma Ltd., a specialty pharmaceutical company that develops innovative therapies using its proprietary sublingual drug delivery technology, WaferiX, announced today that it has, through its subsidiary, entered into an exclusive license agreement with Seelos Therapeutics, Inc., a company focused on developing novel therapeutics for central nervous systems disorders. Under the agreement, iX Biopharma will license to Seelos its lead drug under development, Wafermine, a sublingual racemic ketamine wafer, and other products incorporating R- and S- enantiomers of ketamine utilising the WaferiX technology.

Field Trip Health Ltd., a global leader in the development and delivery of psychedelic therapies, announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Field Trip’s patent application No. 17/364,047 for claims related to FT-104 (informally known as “Isoprocin Glutarate”), Field Trip’s first novel psychedelic molecule in development. Claims in the allowed patent application titled, “Tryptamine Prodrugs”, cover composition of matter, use and manufacturing of a family of hemi-ester compounds of hydroxytryptamines, including FT-104. The international (PCT) patent application relating to FT-104, which was filed in June 2020, has also published (WO 2022/000091) together with the International Search Report (ISR), a first step before expansion into National Phase filings to protect FT-104 in future major markets where Field Trip intends to pursue commercialization should FT-104 achieve regulatory approval. The international (PCT) patent application provides Field Trip with deferred patent filing rights in 150+ countries.

Numinus Wellness Inc., a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, announces that it is rescheduling its Q1 2022 results conference call and reporting of its Q1 2022 financial results to January 20, 2022 (previously January 13, 2022). This change is a result of staffing challenges related to COVID-19. Numinus will now release its financial results for the quarter ended November 30, 2021, after market close on Thursday, January 20, 2022. Interested parties are invited to participate in the Company’s Q1 2022 results conference call and webcast, occurring on January 20, 2022, at 5:30 p.m. Eastern time / 2:30 p.m. Pacific time.

Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. NeonMind Biosciences Inc. has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of NeonMind Biosciences Inc. Please click here for full disclaimer.

Contact Information:

Related posts

Carl Icahn Increases His Stake In Take-Two Interactive To 10.68%


iPad Mini Display Outperformed By Kindle Fire HD & Nexus 7


Foxconn Might Open Manufacturing Plants In The U.S. [REPORT]


Peter Cundill Protégé Tim McElvaine on Investing in Japan [VIDEO]


Set Bing Home Page Image As Lock Screen In Windows 8


Morning Market News: JCP, APO, MCHP, ZIP, ENR, LGF, EA, ATVI, COV, LNT